Author Archives: admin


Stem Cell Clinic > Articles by: admin

Stem Cell-Conventional Treatment Combo Offers New Hope in Fighting Deadly Brain Cancer

By Stem Cell Treatment

Durham, NC (PRWEB) August 07, 2013

A new type of treatment that pairs neural stem cells with conventional cancer fighting therapies is showing promise in animal studies for the most common and deadliest form of adult brain cancer glioblastoma multiforme (GBM). The details are revealed in a groundbreaking study led by Maciej Lesniak, M.D., that appears today in STEM CELLS Translational Medicine.

In this work, we describe a highly innovative gene therapy approach, which is being developed along with the NIH and the FDA. Specifically, our group has developed an allogeneic neural stem cell line that is a carrier for a virus that can selectively infect and break down cancer cells, explained Dr. Lesniak, the University of Chicagos director of neurosurgical oncology and neuro-oncology research at the Brain Tumor Center.

The stem cell line, called HB1.F3 NSC, was recently approved by the FDA for use in a phase I human clinical trial.

GBM remains fatal despite intensive treatment with surgery, radiation and chemotherapy. And while cancer-killing viruses have been used in clinical trials to treat therapeutically resistant and infiltrative tumor burdens throughout the brain, there were major drawbacks, Dr. Lesniak explained.

When you inject a virus into a tumor alone (without a carrier, like NSC), the virus stays at the site of the injection, and does not spread. Moreover, our immune system clears it. By using NSCs, we can achieve a widespread distribution of the virus throughout the tumor mass, since the NSC travel. Also, they act like a stealth fighter, hiding the virus from the immune system. By using NSC loaded with a novel oncolytic adenovirus that selectively targets GBM, along with standard of care that includes chemo-radiotherapy, the team was able to overcome these limitations.

Using mice that had GBM, the research team showed how their neural stem cell line, which is derived from human fetal cells, could significantly increase the median survival time of the mice beyond conventional treatments alone. The addition of chemo-radiotherapy further enhanced the benefits of this novel stem cell-based gene therapy approach.

Our study argues in favor of using stem cells for delivery of oncolytic viruses along with multimodal chemo-radiotherapy for the treatment of patients with GBM, and this is something that we believe warrants further clinical investigation, Dr. Lesniak concluded.

The team is completing final FDA-directed studies and expects to start a human clinical trial, in which a novel oncolytic virus will be delivered via NSCs to patients with newly diagnosed GBM, early in 2014.

Treatment of GMB depends on novel therapies, said Anthony Atala, M.D., Editor of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine. This study establishes that a combination of conventional and gene therapies may be most effective and suggests a protocol for a future clinical investigation.

See the original post:
Stem Cell-Conventional Treatment Combo Offers New Hope in Fighting Deadly Brain Cancer

The most expensive burger in history — and what it means for future …

By Stell Cell Research

Here at Maclean's, we appreciate the written word. And we appreciate you, the reader. We are always looking for ways to create a better user experience for you and wanted to try out a new functionality that provides you with a reading experience in which the words and fonts take centre stage. We believe you'll appreciate the clean, white layout as you read our feature articles. But we don't want to force it on you and it's completely optional. Click "View in Clean Reading Mode" on any article if you want to try it out. Once there, you can click "Go back to regular view" at the top or bottom of the article to return to the regular layout.

Scientist Dr. Mark Post poses with samples of in-vitro meat in a laboratory, at the University of Maastricht in the Netherlands on November 9, 2011. (Francois Lenoir/Reuters)

As long weekend revelers across Canada throw steaks and sausages on the grill, Dr. Mark Post was cooking up something different: a hamburger made of animal stem cells, grown in his lab at Maastricht University in the Netherlands.

The one little five-ounce patty took him years to perfect, at a cost of 300,000 euros, or more than $409,500 (donated by an anonymous investor), making it what must be the most expensive and labour-intensive sandwich patty in history. Some doubted it could be done. As the burger was unveiled in Londonthen bitten, chewed, swallowed and consumed, for all the world to seePosts burger was redefining meat as we know it. This is the food of the future.

Post, a medical doctor, has been attempting to create tissues in the lab for almost a decade. The applications are huge: engineered human tissues could be used to test drugs, for example, or to treat many diseases where the body wastes away.

To Post, the food application started out as an interesting side project, one that soon stole the spotlight from his other work. Meat for consumption is in theory, much easier to grow, he told Macleans in an interview in 2012. The tissue does not need to physically integrate into the body. I considered it a closer goal to reach, he says, and a very important one.

Indeed, the global appetite for meat is growing.

Livestock production already takes up 30 per cent of the land surface on our planet, says a 2006 United Nations report, producing more greenhouse gas emissions than all our cars and trucks, combined. According to Patrick O. Brown of Stanford University, eating one four-ounce hamburger is the equivalent of leaving a bathroom faucet running round-the-clock for a week. Developing nations are increasingly emulating the meat-heavy Western diet, and it isnt sustainable. We are heading towards a meat shortage worldwide, Post says. Instead of producing beef, pork and poultry on massive industrial farms, in the near future, he predicts, well be growing it in factories. And while this first hamburger was incredibly expensive to make, as techniques are perfected and lab-grown stem-cell burgers can be mass-produced, the cost will go down; one day it could be lower than the price of traditionally raised meat, which is expected to rise.

Of course, growing a minced hamburger pattylet alone a dense, fat-marbled steakisnt a simple task. Post and his team harvested stem cells from a cows muscle tissue, and bathed them in a special formula of nutrients. As these cells start to differentiate into muscle cells, theyre hooked to attachment points (Post has used Velcro) to create tiny strips of tissue, like a tendon. Eventually, they start to contract on their own. The downside for animal lovers is that you still need animals, a donor herd to provide stem cells, Post says. But compared to factory farming today, the number would be very small. If we grew all our meat in a lab, Post believes, the number of livestock worldwide could be reduced by a factor of one millionthe equivalent of reducing 10 billion livestock animals on the planet to 10,000. This would free up land, water, and other resources, while making sure remaining livestock didnt suffer a death fraught with the issues of large-scale slaughter.

Other than Post, only a handful of scientists are working on lab-grown meat; others believe the future lies in plant-based substitutes, ones so good they could fool even the most discerning palate, although Post maintains that we humans will always have an appetite for the real thing.

Read the original post:
The most expensive burger in history — and what it means for future ...

Hypoplastic Left Heart Syndrome Surgical Management and Stem Cell Therapy Part 2 – Mayo Clinic – Video

By Uncategorized


Hypoplastic Left Heart Syndrome Surgical Management and Stem Cell Therapy Part 2 - Mayo Clinic
In this video, Mayo Clinic pediatric heart surgeon Harold Burkhart, M.D., provides an overview of the current clinical trial underway at Mayo Clinic. The vid...

By: asbestoslawyers1

More:
Hypoplastic Left Heart Syndrome Surgical Management and Stem Cell Therapy Part 2 - Mayo Clinic - Video

StemCells, Inc. Announces Webcast to Discuss Second Quarter 2013 Financial Results and Business Update

By Stem Cell Treatment

NEWARK, Calif., Aug. 5, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it will release financial results for the second quarter ended June 30, 2013 after the market close on Wednesday, August 7. In connection with this announcement, StemCells will host a conference call and webcast to discuss its results and an update on its business at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) the same day. Eliseo Salinas, MD, Executive Vice President and Head of Research & Development at StemCells, will be on the call to discuss the Company's recently announced two-year data in patients with Pelizaeus-Merzbacher disease (PMD).

Interested parties are invited to listen to the call over the Internet by accessing the Investors section of the Company's website at http://www.stemcellsinc.com. Webcast participants should allot extra time before the webcast begins to register and, if necessary, download and install audio software.

An archived version of the webcast will also be available for replay on the Company's website beginning approximately two hours following the conclusion of the live call and continuing for a period of 30 days.

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC(R) cells (purified human neural stem cells), is currently in development as a potential treatment for a broad range of central nervous system disorders. In a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children, the Company has shown preliminary evidence of progressive and durable donor-derived myelination in all four patients transplanted with HuCNS-SC cells. The Company is also conducting a Phase I/II clinical trial in chronic spinal cord injury in Switzerland and Canada and has reported positive interim data for the first three patients. The Company is also conducting a Phase I/II clinical trial in dry age-related macular degeneration (AMD) at two trial sites in the US. In addition, the Company is pursuing preclinical studies in Alzheimer's disease, with funding support from the California Institute for Regenerative Medicine (CIRM). StemCells also markets stem cell research products, including media and reagents, under the SC Proven(R) brand. Further information about StemCells is available at http://www.stemcellsinc.com.

Apart from statements of historical fact, the text of this press release constitutes forward-looking statements within the meaning of the U.S. securities laws, and is subject to the safe harbors created therein. These forward-looking statements speak only as of the date of this news release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management's current views and are based on certain assumptions that may or may not ultimately prove valid. The Company's actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including those described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2012 and in its subsequent reports on Forms 10-Q and 8-K.

See the article here:
StemCells, Inc. Announces Webcast to Discuss Second Quarter 2013 Financial Results and Business Update

BioRestorative Therapies Receives Approval to Conduct Retrospective Safety Study on its Bulging/Herniated Disc Procedure

By Stem Cell Treatment

JUPITER, Fla., Aug. 6, 2013 /PRNewswire/ --BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTC BB: BRTX), a life sciences company focused on developing stem cell based cellular therapies for various personal medical applications, today announced that it has received approval from the Western Institutional Review Board ("the Board") to complete a retrospective safety study on selected subjects previously treated by the Company's brtxDISC bulging and herniated disc procedure. The study is titled "Re-consenting and Follow-Up of Adults from a Retrospective Study Using Autologous Transplantation of Marrow Derived Mesenchymal Stem Cells to Degenerated Intervertebral Disc."

Study objectives are to determine the safety of subjects who received transplants of their own stem cells into their disc, using MRI and Quality of Life Questionnaires. TheBoard requires that all subjects must be able to consent for themselves to be enrolled in the study, which has been approved to take place at the Centeno-Schultz Clinic in Broomfield, Colorado.

The approval allows BRT to retrospectively collect and analyze clinical data on selected subjects who previously have been treated for bulging or herniated disc disease with the Company's novel brtxDISC procedure. These procedures were performed using BRT's proprietary therapeutic delivery device cannula system and its proprietary culture method isolating a selective population of mesenchymal stem cells. BRT expects to complete the study within a six-month period.

"This is a significant milestone in taking our brtxDISC procedure closer towards an FDA meeting to seek approval for the commencement of our clinical trial. We look forward to collecting this data with the ambition of meeting the safety requirements necessary for us to receive approval and start our trial," commented Mark Weinreb, Chief Executive Officer of BioRestorative Therapies. "Our goal is to compile and present the necessary data to the FDA with the goal of initiating a Phase I or Phase II clinical trial in the early part of next year."

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. ("BRT"),www.biorestorative.com, develops medical procedures using cell and tissue protocols, primarily involving adult stem cells, designed for patients to undergo minimally invasive cellular-based treatments. BRT is developing the following scientific initiatives:

The Company also offers plant stem cell-based facial creams and beauty products under theStem Pearlsbrand atwww.stempearls.com.

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

Investor Contact:Jared Mitchell ProActive Capital 646.863.6274 jmitchell@proactivecapital.com

Media Contact:Sandra Lee ProActive Capital 646.862.4608 slee@proactivecapital.com

Read more:
BioRestorative Therapies Receives Approval to Conduct Retrospective Safety Study on its Bulging/Herniated Disc Procedure

PRC: Foreign docs doing stem cell therapy in PH must get special temporary permits

By Stem Cell Treatment

By: Jet Villa, InterAksyon.com August 6, 2013 4:34 PM

InterAksyon.com The online news portal of TV5

MANILA, Philippines - Amid a flurry of reports about unregulated procedures that have led to serious injury or even deaths, the Professional Regulation Commission (PRC) is now requiring foreign doctors wishing to practice stem cell therapy in the Philippines to obtain a special temporary permit (STP).

In a position statement, the Professional Regulatory Board of Medicine (PRBOM) said foreign doctors must submit proof of education, training and clinical experience and actual practice in the field of stem cell therapy, plus a current license to practice authenticated by the Philippine Embassy/Consulate in the country of origin when they apply for the special permits.

The board warned: Any foreign physician who practices the professionwithout a STP will be criminally liable for illegal practice of medicine.And, it added, those who have aided and abetted the foreign physicianspractice of the profession are also criminally liable.

The position paper was signed by PRBOM chairman Dr. Edgardo Fernando and members doctors Miguel Noche Jr., Florentino Doble, Restituto de Ocampo, Jose Cueto Jr., and Mildred Pareja.

Controversy hounds new group

The position statement on stem cell therapy was issued amid a growing rift among doctors over recent controversial cases, including several lawmakers who had procedures done, but whose conditions worsened.

One newly-founded group of doctors doing stem-cell transplant, the Philippine Society of Stem Cell Medicine (PSSCM), has been pitted by the controversy against the Philippine College of Physicians, Philippine Society of General Internal Medicine (PSGIM), Philippine Society of Hematology and Blood Transfusion (PSHBT) andPhilippine College of Chest Physicians (PCCP). The latter groups all believe thatPSSCM's practices are unethical as it charges huge fees from patients for stem cell procedures that are still under clinical trial.

The PRBOM has backed the Department of Health in issuing Administrative Order 2013-0012 providing the guidelines for stem cell, cell-based therapy in the country. "The practice of stem cell therapy does not constitute standard care at the present time. The claim that it offers cure to numerous diseases and conditions has not been proven through scientific research and documentation, the PRBOM said. Right now, it said, "there is difficulty verifying claims of practitioners and institutions regarding the effectivity ofavailable treatment modalities.

Here is the original post:
PRC: Foreign docs doing stem cell therapy in PH must get special temporary permits

One lab-grown hamburger, coming up – Blog Central, Kate Lunau …

By Stell Cell Research

Here at Maclean's, we appreciate the written word. And we appreciate you, the reader. We are always looking for ways to create a better user experience for you and wanted to try out a new functionality that provides you with a reading experience in which the words and fonts take centre stage. We believe you'll appreciate the clean, white layout as you read our feature articles. But we don't want to force it on you and it's completely optional. Click "View in Clean Reading Mode" on any article if you want to try it out. Once there, you can click "Go back to regular view" at the top or bottom of the article to return to the regular layout.

Scientist Dr. Mark Post poses with samples of in-vitro meat in a laboratory, at the University of Maastricht in the Netherlands on November 9, 2011. (Francois Lenoir/Reuters)

Its high time for summer barbecue season. On Aug. 5, as long weekend revelers across Canada throw steaks and sausages on the grill, Dr. Mark Post will be cooking up something very different: a hamburger made of animal stem cells, grown in his lab at Maastricht University in the Netherlands.

This one little five-ounce patty has taken him years to perfect, at a cost of 300,000 euros, or over $409,500 (donated by an anonymous investor), making it what must be the most expensive and labour-intensive sandwich patty in history. Some doubted it could be done. As the burger is unveiled in Londonthen bitten, chewed, swallowed and consumed, for all the world to seePosts burger will redefine meat as we know it. This is the food of the future.

Post, a medical doctor, has been attempting to create tissues in the lab for almost a decade. The applications are huge: engineered human tissues could be used to test drugs, for example, or to treat many diseases where the body wastes away. To Post, the food application started out as an interesting side project, one that soon stole the spotlight from his other work. Meat for consumption is in theory, much easier to grow, he told Macleans in an interview in 2012. The tissue does not need to physically integrate into the body. I considered it a closer goal to reach, he says, and a very important one.

Indeed, the global appetite for meat is growing. Livestock production already takes up 30 per cent of the land surface on our planet, says a 2006 United Nations report, producing more greenhouse gas emissions than all our cars and trucks, combined. According to Patrick O. Brown of Stanford University, eating one four-ounce hamburger is the equivalent of leaving a bathroom faucet running round-the-clock for a week. Developing nations are increasingly emulating the meat-heavy Western diet, and it isnt sustainable. We are heading towards a meat shortage worldwide, Post says. Instead of producing beef, pork and poultry on massive industrial farms, in the near future, he predicts, well be growing it in factories. And while this first hamburger was incredibly expensive to make, as techniques are perfected and lab-grown stem-cell burgers can be mass-produced, the cost will go down; one day it could be lower than the price of traditionally raised meat, which is expected to rise.

Of course, growing a minced hamburger pattylet alone a dense, fat-marbled steakisnt a simple task. Post and his team harvested stem cells from a cows muscle tissue, and bathed them in a special formula of nutrients. As these cells start to differentiate into muscle cells, theyre hooked to attachment points (Post has used Velcro) to create tiny strips of tissue, like a tendon. Eventually, they start to contract on their own. The downside for animal lovers is that you still need animals, a donor herd to provide stem cells, Post says. But compared to factory farming today, the number would be very small. If we grew all our meat in a lab, Post believes, the number of livestock worldwide could be reduced by a factor of one millionthe equivalent of reducing 10 billion livestock animals on the planet to 10,000. This would free up land, water, and other resources, while making sure remaining livestock didnt suffer a death fraught with the issues of large-scale slaughter.

Other than Post, only a handful of scientists are working on lab-grown meat; others believe the future lies in plant-based substitutes, ones so good they could fool even the most discerning palate, although Post maintains that we humans will always have an appetite for the real thing. Worldwide, the meat-eater population is going to grow. Theres no doubt about that, he says. Posts hamburger is a powerful proof of concept, an important first step. As we begin to unravel the implications of this one burgerfor science, for health care, and for the food supply that feeds everyone on the planetwell be watching on Aug. 5, with bated breath, wondering what, exactly, it tastes like.

Anyone who wants to follow along can watch a livestream of the burger consumption on Aug. 5 atculturedbeef.net.

See original here:
One lab-grown hamburger, coming up - Blog Central, Kate Lunau ...

One lab-grown hamburger, coming up – Blog Central, Kate Lunau …

By Stell Cell Research

Here at Macleans, we appreciate the written word. And we appreciate you, the reader. We are always looking for ways to create a better user experience for you and wanted to try out a new functionality that provides you with a reading experience in which the words and fonts take centre stage. We believe youll appreciate the clean, white layout as you read our feature articles. But we dont want to force it on you and its completely optional. Click View in Clean Reading Mode on any article if you want to try it out. Once there, you can click Go back to regular view at the top or bottom of the article to return to the regular layout.

Scientist Dr. Mark Post poses with samples of in-vitro meat in a laboratory, at the University of Maastricht in the Netherlands on November 9, 2011. (Francois Lenoir/Reuters)

Its high time for summer barbecue season. On Aug. 5, as long weekend revelers across Canada throw steaks and sausages on the grill, Dr. Mark Post will be cooking up something very different: a hamburger made of animal stem cells, grown in his lab at Maastricht University in the Netherlands.

This one little five-ounce patty has taken him years to perfect, at a cost of 300,000 euros, or over $409,500 (donated by an anonymous investor), making it what must be the most expensive and labour-intensive sandwich patty in history. Some doubted it could be done. As the burger is unveiled in Londonthen bitten, chewed, swallowed and consumed, for all the world to seePosts burger will redefine meat as we know it. This is the food of the future.

Post, a medical doctor, has been attempting to create tissues in the lab for almost a decade. The applications are huge: engineered human tissues could be used to test drugs, for example, or to treat many diseases where the body wastes away. To Post, the food application started out as an interesting side project, one that soon stole the spotlight from his other work. Meat for consumption is in theory, much easier to grow, he told Macleans in an interview in 2012. The tissue does not need to physically integrate into the body. I considered it a closer goal to reach, he says, and a very important one.

Indeed, the global appetite for meat is growing. Livestock production already takes up 30 per cent of the land surface on our planet, says a 2006 United Nations report, producing more greenhouse gas emissions than all our cars and trucks, combined. According to Patrick O. Brown of Stanford University, eating one four-ounce hamburger is the equivalent of leaving a bathroom faucet running round-the-clock for a week. Developing nations are increasingly emulating the meat-heavy Western diet, and it isnt sustainable. We are heading towards a meat shortage worldwide, Post says. Instead of producing beef, pork and poultry on massive industrial farms, in the near future, he predicts, well be growing it in factories. And while this first hamburger was incredibly expensive to make, as techniques are perfected and lab-grown stem-cell burgers can be mass-produced, the cost will go down; one day it could be lower than the price of traditionally raised meat, which is expected to rise.

Of course, growing a minced hamburger pattylet alone a dense, fat-marbled steakisnt a simple task. Post and his team harvested stem cells from a cows muscle tissue, and bathed them in a special formula of nutrients. As these cells start to differentiate into muscle cells, theyre hooked to attachment points (Post has used Velcro) to create tiny strips of tissue, like a tendon. Eventually, they start to contract on their own. The downside for animal lovers is that you still need animals, a donor herd to provide stem cells, Post says. But compared to factory farming today, the number would be very small. If we grew all our meat in a lab, Post believes, the number of livestock worldwide could be reduced by a factor of one millionthe equivalent of reducing 10 billion livestock animals on the planet to 10,000. This would free up land, water, and other resources, while making sure remaining livestock didnt suffer a death fraught with the issues of large-scale slaughter.

Other than Post, only a handful of scientists are working on lab-grown meat; others believe the future lies in plant-based substitutes, ones so good they could fool even the most discerning palate, although Post maintains that we humans will always have an appetite for the real thing. Worldwide, the meat-eater population is going to grow. Theres no doubt about that, he says. Posts hamburger is a powerful proof of concept, an important first step. As we begin to unravel the implications of this one burgerfor science, for health care, and for the food supply that feeds everyone on the planetwell be watching on Aug. 5, with bated breath, wondering what, exactly, it tastes like.

Anyone who wants to follow along can watch a livestream of the burger consumption on Aug. 5 atculturedbeef.net.

Continued here: One lab-grown hamburger, coming up Blog Central, Kate Lunau

Continued here:
One lab-grown hamburger, coming up – Blog Central, Kate Lunau ...

World-class Stem Cell Research Centre for Queenstown

By Stem Cell Treatment

A world-class research and treatment centre that will specialise in using the bodys own blood cells to heal sports injuries and arthritis is planned for Queenstown within the year according to one of the worlds leading experts on Stem Cell Therapy.

Speaking at the New Zealand College of Appearance Medicine Conference in Queenstown yesterday (Thursday August 1), Professor Boyd said Queenstown was at the forefront of Platelet Rich Plasma therapy in the country and was an "obvious choice" to expand into Stem Cell Therapy.

Used in the USA for ten years and Australia for five years, Platelet Rich Plasma (PRP) is already available in New Zealand thanks to Queenstown Regenerative Medicine (QRM) an internationally-linked Queenstown clinic.

Endorsed worldwide by global sports superstars such as Tiger Woods and Kobe Bryant, PRP is a process by which a small amount of blood is taken from the patient and then spun in a centrifuge which automatically produces PRP (blood plasma with a concentrated amount of platelets).

Platelets are the bloods "ambulance, containing over 20 factors important for tissue repair and keeping the body healthy.

The process takes about 15 to 20 minutes and increases the concentration of platelets by up to 500%. The PRP is then injected back into the patients affected area, which reduces inflammation and hence pain, while also stimulating the healing of the tendon or ligament and maybe even cartilage. It can be used in shoulders, knees, ankles, hips, elbows, wrists and much more.

Stem Cell Therapy differs from PRP as it introduces new adult stem cells into damaged tissue in order to treat disease or injury. The stem cells are grown outside the body and then transplanted into the body. It is a lengthier, more involved process, whereas PRP is done purely by injection.

"PRP is thus like the bloods "ambulance" - packed with over 20 factors which not only cause clotting when needed, but can dampen inflammation and reduce pain while also triggering repair processes. Instead of delivering just one signal as common drugs do, they provide a factory of helpers.

"Stem Cell Therapy to heal sports and other injuries has proven to be a great success in clinical trials in the USA and UK, and its our aim to ensure this leading edge therapy is available in New Zealand," said Professor Boyd.

"Our task as researchers is to understand how the body develops in the embryo, is maintained in adults and how it tries to trigger its own repair in disease states.

Read the rest here:
World-class Stem Cell Research Centre for Queenstown

→←